Sean McClain, the Chief Executive Officer of Absci Corp, has disclosed a transaction involving 79,860 shares of the company's common stock. This transaction, reported on October 30, 2026, is significant as it relates to tax withholding obligations following the vesting of performance-based restricted stock units (RSUs).

Absci Corp operates within the biotechnology sector, specifically in the commercial physical and biological research industry. The company is known for its innovative approaches to drug development and production, making it a key player in its field.

The recent filing indicates that the shares were withheld to cover tax obligations associated with the vesting of 200,000 performance-based RSUs, which were contingent on achieving a closing stock price of at least $12.00 per share. Following this transaction, McClain retains ownership of 8,552,402 shares of Absci Corp.

This transaction may impact various stakeholders, including investors and employees, as it highlights the company's executive compensation strategies and the performance metrics tied to stock options. The biotechnology sector, in general, is closely watching how companies manage executive pay and performance incentives, especially in a competitive market.

The filing does not say what happens next regarding further disclosures or additional transactions.

Transaction Details

The transaction involved the withholding of 79,860 shares of common stock at a price of $12.10 per share. This withholding was specifically to meet tax obligations related to the vesting of the performance-based RSUs, which were contingent on achieving a closing stock price of at least $12.00 per share.

"Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of 200,000 performance-based RSUs upon achievement of a closing stock price equal to or exceeding $12.00 per share."

Company Background

Absci Corp, formerly known as AbSci Corp, AbSci, Inc., and AbSci, LLC, is classified under the Standard Industrial Classification (SIC) code for services related to commercial physical and biological research. The company is headquartered in Vancouver, Washington, and has a fiscal year-end on December 31.

The filing does not include any information regarding future plans for additional stock transactions or changes in executive compensation structure.